Discovery & Mechanism Intelligence
Reveal response-defining tissue biology for target selection and MOA hypotheses
Software · HybridCompany source
Company profile
About PredxBio
PredxBio is a precision healthcare technology company that provides tissue intelligence solutions for pharmaceutical drug development. The company's flagship SpaceIQ platform transforms complex spatial and multi-omic tissue data into explainable, decision-ready insights that guide drug development from early discovery through clinical programs and portfolio strategy. By resolving functional cell states, spatial microenvironments, and cell-cell interactions, PredxBio uncovers response-driving biology that conventional analyses miss. The platform integrates unbiased spatial analytics with explainable AI to systematically characterize tissue organization, functional states, and molecular interactions across spatial imaging and multi-omic data. SpaceIQ supports three key stages of drug development: Discovery & Mechanism Intelligence to reveal response-defining tissue biology for target selection; Translational & Clinical Readiness to define predictive tissue-based biomarkers and stratify patient populations; and Trial & Program-Scale Decision Support to guide trial strategy and enable reproducible tissue intelligence across studies. The company serves pharmaceutical companies, biotech firms, and drug developers, helping teams move from exploratory tissue analysis to confident, development-ready decisions. PredxBio's approach enables earlier go/no-go decisions, stronger biomarker strategies, patient stratification based on tissue-level biology, and more efficient clinical development programs.
Company description PredxBio official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at PredxBio?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Oncology
Who it serves
- Biotech
- Drug developers
- Pharma
Deployment & integration
Hybrid deployment with recorded integration context.
Geographic context
MarketsUSA
Company sourceOfficial website
Company milestones
Platform expansion
Hosted Spatial Intelligence Summit in Pittsburgh (November 2025). Presenting 6 posters at AACR 2026 conference (April 17-22, 2026, San Diego). Released white paper on Spatially Intelligent Platform.
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
SpaceIQ
Decision intelligence platform for spatial tissue analysis in drug development
Platform · HybridCompany source
Translational & Clinical Readiness
Define predictive tissue-based biomarkers and stratify patient populations
Software · HybridCompany source
Trial & Program-Scale Decision Support
Apply consistent tissue intelligence across studies to guide trial strategy
Software · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
NADPH oxidase 2 activity disrupts Calmodulin/CaMKIIα complex via redox modifications of CaMKIIα-contained Cys30 and Cys289: Implications in Parkinson's disease.Redox biology · Sep 1, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Earlier go/no-go decisions
Drug development decision-making
Stronger biomarker strategies
Clinical development programs
More efficient clinical development
Trial optimization and patient stratification
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
B. Dusty Majumdar
Chief Executive Officer
Joe Camaratta
Sr. VP Business Development
Bruce Campbell
VP Software Engineering
06 · Company updates
Updates from PredxBio
Recent articles published on PredxBio's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.